Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 6

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 6
---
 our ImmTAC (

#### I
mmune

#### m
obilizing

#### m
onoclonal

#### T
CRs

#### A
gainst

#### C
ancer) portfolio, including KIMMTRAK and the PRAME-targeted brenetafusp.

<div align='center'>S-1</div>

TABLE OF CONTENTS

Our Pipeline

| 1 | Platinum refractory or resistant serous ovarian carcinoma. |

| 2 | NSCLC = Non-small cell lung cancer |

| 3 | Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. |

| 4 | Program is not HLA restricted (i.e. universal for all populations). |

| 5 | Submission |

Corporate Information Immunocore Holdings plc was incorporated as Immunocore Holdings Limited, a private limited company under the laws of England and Wales on January 7, 2021 with company registration number 13119746 for the purpose of becoming the holding company of Immunocore Limited. Immunocore Limited was incorporated under the laws of England and Wales in December 2007, with company registration number 06456207. Our registered office is located at 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom, and the telephone number of our registered office is +44 (0)1235 438600. Our principal executive offices in the United States are located at Six Tower Bridge, Suite 200, 181 Washington Street, Conshohocken, Pennsylvania 19428 and 9801 Washingtonian Boulevard, Suite 800, Gaithersburg, Maryland 20878, United States, and our U.S. telephone number is +1 484 534 5261. Our website address is www.immunocore.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus supplement, and you should not consider information on our website to be part of this prospectus supplement. Our agent for service of process in the United States is Immunocore, LLC.

S-2

#### TABLE OF CONTENTS

### THE OFFERING

#### Securities Offered by the Selling Securityholders
$150,000,000 aggregate principal amount of the notes and up to 1,584,014 note conversion ADSs

#### Use